Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AMG 820 + pembrolizumab
- Development stage
- Discontinued
- Lead developer
- Amgen
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
AMG 820 + pembrolizumab is a combination therapy consisting of AMG 820, a fully human antagonistic IgG2 monoclonal antibody targeting CSF1R (colony-stimulating factor 1 receptor), and pembrolizumab (KEYTRUDA), a humanized monoclonal antibody targeting PD-1 (programmed cell death protein 1). This combination was designed to enhance anti-tumor activity by simultaneously targeting tumor-associated macrophages through CSF1R inhibition and activating T lymphocytes through PD-1 blockade. The recommended dose was 1100 mg AMG 820 plus 200 mg pembrolizumab administered intravenously every 3 weeks.
- Brand names
- Keytruda
- Other names
- anti-CSF1R antibodyanti-CSF-1R antibodyanti-CSF 1R antibodyanti-colony-stimulating factor 1 receptor antibody
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)CSF1R (Macrophage colony-stimulating factor receptor)
Beyond the preview
Go deeper on AMG 820 + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AMG 820 + pembrolizumab.